Investor News no. 01/2019
To: NASDAQ Copenhagen A/S
Copenhagen, Denmark, 26 February 2019
Veloxis to Host Conference Call Following Release of 2018 Annual Report
As previously announced, Veloxis Pharmaceuticals A/S (NASDAQ: VELO) will release its 2018 Annual Report on Wednesday, February 27, 2019. In connection with the release, Veloxis’s Executive Management will host a conference call to discuss the 2018 financial results on Thursday, February 28, 2019 at 4:00 p.m. CET (Denmark); 3:00 p.m. GST (London); and 10:00 a.m. EST (New York).
To access the live conference call, please dial one of the following numbers:
+45 32 72 75 18 (Denmark)
+44 (0) 203 009 5710 (UK)
+1 917 720 0178 (USA)
Confirmation Code: 2466359
Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com.
For more information, please contact:
| Craig A. Collard | Ira Duarte | |
| President & CEO | CFO | |
| Phone: + 1 919 591 3090 | Phone: +1 919 591 3090 | |
| Email: cac@veloxis.com | Email: idu@veloxis.com |
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR® (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com.
Attachment
